HK Stock Market Move | KEYMED BIO-B(02162) rose by over 5%. The company plans to go public on the Science and Technology Innovation Board. In the first half of the year, sales increased by 132% year-on-year.

KEYMED BIO-B (02162) surged over 5%, and as of the time of writing, it increased by 5.06%, trading at HKD 80.95 with a transaction volume of HKD 82.7412 million. In terms of news, KEYMED BIO-B announced that on August 19, 2026, the Companys board meeting resolved to propose the issuance of common shares listed on the Shanghai Stock Exchange Science and Technology Innovation Board (STAR Market) and traded in RMB (proposed issuance of RMB shares). The proposed issuance of RMB shares is subject to and dependent on (including) market conditions, further approval by the board of directors, approval by the Company's shareholders at the Companys general meeting, and obtaining necessary regulatory approvals. Previously, KEYMED BIO-B issued a positive profit warning, indicating that the company expects to achieve a profit of no less than RMB 1.2 billion in the first half of 2026. The company's innovative product, Kangyueda, has shown outstanding clinical value, resulting in a continuous increase in the number of covered patients, achieving sales revenue of RMB 390 million in the first half of 2026, representing a year-on-year growth of 132%, providing the company with sustained income.